263 related articles for article (PubMed ID: 12603833)
1. Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease.
Lastres-Becker I; de Miguel R; De Petrocellis L; Makriyannis A; Di Marzo V; Fernández-Ruiz J
J Neurochem; 2003 Mar; 84(5):1097-109. PubMed ID: 12603833
[TBL] [Abstract][Full Text] [Related]
2. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.
Lastres-Becker I; Hansen HH; Berrendero F; De Miguel R; Pérez-Rosado A; Manzanares J; Ramos JA; Fernández-Ruiz J
Synapse; 2002 Apr; 44(1):23-35. PubMed ID: 11842443
[TBL] [Abstract][Full Text] [Related]
3. Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease.
de Lago E; Urbani P; Ramos JA; Di Marzo V; Fernández-Ruiz J
Brain Res; 2005 Jul; 1050(1-2):210-6. PubMed ID: 15975564
[TBL] [Abstract][Full Text] [Related]
4. Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease.
Lastres-Becker I; Fezza F; Cebeira M; Bisogno T; Ramos JA; Milone A; Fernández-Ruiz J; Di Marzo V
Neuroreport; 2001 Jul; 12(10):2125-9. PubMed ID: 11447320
[TBL] [Abstract][Full Text] [Related]
5. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.
Cabranes A; Venderova K; de Lago E; Fezza F; Sánchez A; Mestre L; Valenti M; García-Merino A; Ramos JA; Di Marzo V; Fernández-Ruiz J
Neurobiol Dis; 2005 Nov; 20(2):207-17. PubMed ID: 16242629
[TBL] [Abstract][Full Text] [Related]
6. UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders.
de Lago E; Fernández-Ruiz J; Ortega-Gutiérrez S; Cabranes A; Pryce G; Baker D; López-Rodríguez M; Ramos JA
Eur Neuropsychopharmacol; 2006 Jan; 16(1):7-18. PubMed ID: 16006105
[TBL] [Abstract][Full Text] [Related]
7. Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence.
de Lago E; de Miguel R; Lastres-Becker I; Ramos JA; Fernández-Ruiz J
Brain Res; 2004 May; 1007(1-2):152-9. PubMed ID: 15064146
[TBL] [Abstract][Full Text] [Related]
8. Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors.
Golech SA; McCarron RM; Chen Y; Bembry J; Lenz F; Mechoulam R; Shohami E; Spatz M
Brain Res Mol Brain Res; 2004 Dec; 132(1):87-92. PubMed ID: 15548432
[TBL] [Abstract][Full Text] [Related]
9. Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues.
Di Marzo V; Lastres-Becker I; Bisogno T; De Petrocellis L; Milone A; Davis JB; Fernandez-Ruiz JJ
Eur J Pharmacol; 2001 May; 420(2-3):123-31. PubMed ID: 11408034
[TBL] [Abstract][Full Text] [Related]
10. Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications.
Tzavara ET; Li DL; Moutsimilli L; Bisogno T; Di Marzo V; Phebus LA; Nomikos GG; Giros B
Biol Psychiatry; 2006 Mar; 59(6):508-15. PubMed ID: 16199010
[TBL] [Abstract][Full Text] [Related]
11. Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors.
Martín AB; Fernandez-Espejo E; Ferrer B; Gorriti MA; Bilbao A; Navarro M; Rodriguez de Fonseca F; Moratalla R
Neuropsychopharmacology; 2008 Jun; 33(7):1667-79. PubMed ID: 17957223
[TBL] [Abstract][Full Text] [Related]
12. The anandamide transport inhibitor AM404 reduces ethanol self-administration.
Cippitelli A; Bilbao A; Gorriti MA; Navarro M; Massi M; Piomelli D; Ciccocioppo R; Rodríguez de Fonseca F
Eur J Neurosci; 2007 Jul; 26(2):476-86. PubMed ID: 17650118
[TBL] [Abstract][Full Text] [Related]
13. Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors.
Sagredo O; Ramos JA; Decio A; Mechoulam R; Fernández-Ruiz J
Eur J Neurosci; 2007 Aug; 26(4):843-51. PubMed ID: 17672854
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effect of intrathecally administered AM404, an endocannabinoid reuptake inhibitor, on neuropathic pain in a rat chronic constriction injury model.
Haranishi Y; Hara K; Terada T
Pharmacol Rep; 2021 Jun; 73(3):820-827. PubMed ID: 33783763
[TBL] [Abstract][Full Text] [Related]
15. The anandamide transport inhibitor AM404 activates vanilloid receptors.
Zygmunt PM; Chuang H; Movahed P; Julius D; Högestätt ED
Eur J Pharmacol; 2000 May; 396(1):39-42. PubMed ID: 10822052
[TBL] [Abstract][Full Text] [Related]
16. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding.
Gómez R; Navarro M; Ferrer B; Trigo JM; Bilbao A; Del Arco I; Cippitelli A; Nava F; Piomelli D; Rodríguez de Fonseca F
J Neurosci; 2002 Nov; 22(21):9612-7. PubMed ID: 12417686
[TBL] [Abstract][Full Text] [Related]
17. A structure/activity relationship study on arvanil, an endocannabinoid and vanilloid hybrid.
Di Marzo V; Griffin G; De Petrocellis L; Brandi I; Bisogno T; Williams W; Grier MC; Kulasegram S; Mahadevan A; Razdan RK; Martin BR
J Pharmacol Exp Ther; 2002 Mar; 300(3):984-91. PubMed ID: 11861807
[TBL] [Abstract][Full Text] [Related]
18. Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease.
González S; Scorticati C; García-Arencibia M; de Miguel R; Ramos JA; Fernández-Ruiz J
Brain Res; 2006 Feb; 1073-1074():209-19. PubMed ID: 16412990
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens.
Ross RA; Gibson TM; Brockie HC; Leslie M; Pashmi G; Craib SJ; Di Marzo V; Pertwee RG
Br J Pharmacol; 2001 Feb; 132(3):631-40. PubMed ID: 11159715
[TBL] [Abstract][Full Text] [Related]
20. Role of the endocannabinoid and endovanilloid systems in an animal model of schizophrenia-related emotional processing/cognitive deficit.
Almeida V; Levin R; Peres FF; Suiama MA; Vendramini AM; Santos CM; Silva ND; Zuardi AW; Hallak JEC; Crippa JA; Abílio VC
Neuropharmacology; 2019 Sep; 155():44-53. PubMed ID: 31103618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
